Endo EPS beats by $0.25, beats on revenue
- BySeeking Alpha-
By Nate Raymond and Brendan Pierson (Reuters) - Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive...
By Nate Raymond and Brendan Pierson (Reuters) - Four drugmakers, including Johnson & Johnson (NYSE:JNJ) and Teva Pharmaceutical Industries (NYSE:TEVA) Ltd, will go to trial on...
Shares of Bausch Health Companies (NYSE:BHC) Inc. BHC were down 7.3% on disappointing results for the first quarter of 2020. The company lowered its revenue guidance for...
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.